{"schema_version":"secwatch.filing_event.v1","accession":"0001372514-23-000097","form_type":"8-K","ticker":"KPRX","cik":"0001372514","company_name":"KIORA PHARMACEUTICALS INC","filed_at":"2023-06-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.601405+00:00","generated_at":"2026-06-14T06:27:04.411230+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Kiora Pharmaceuticals closes $6.3M underwritten public offering, including full over-allotment","bullets":["Gross proceeds of $6.3M from offering of common stock, Series F convertible preferred, and Class C/D warrants.","Net proceeds to Kiora approximately $5.6M after underwriting discounts and offering expenses.","Underwriter's over-allotment option fully exercised, adding 750,000 common shares and warrants.","Series F preferred convertible into common; holder limited to 4.99% beneficial ownership (can increase to 9.99%).","Class C warrants expire in 5 years, Class D in 1 year; both have initial exercise price of $1.10 per share."],"urls":{"canonical":"https://secwatch.observer/filing/0001372514-23-000097","json":"https://secwatch.observer/filing/0001372514-23-000097.json","markdown":"https://secwatch.observer/filing/0001372514-23-000097.md","text":"https://secwatch.observer/filing/0001372514-23-000097.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1372514/000137251423000097/0001372514-23-000097-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1372514/000137251423000097/kprx-20230602.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T06:27:04.411230+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7734b4cb9587915df105e3ad6311d1a67ffbb07f","claim":"KIORA PHARMACEUTICALS INC entered into Underwriting Agreement with Ladenburg Thalmann & Co. Inc. valued at Underwriting Agreement for public offering of common stock, preferred stock, and warrants, net proce (effective 2023-06-02).","evidence_excerpt":"On June 2, 2023, Kiora Pharmaceuticals, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Ladenburg Thalmann & Co. Inc., as underwriter (the “Underwriter”), pursuant to which the Company agreed to issue and sell, in a firm commitment underwritten public offering by the Company (the “Public Offering”), (i) 1,447,628 shares of common stock (the “Common Shares”), (ii) 3,908 shares of Series F Convertible Preferred Stock (the “Preferred Shares”) convertible into up to 3,552,372 shares of common stock, (iii) Class C Warrants (the “Class C Warrants”) to purchase up to 5,000,000 shares of common stock, and (iv) Class D Warrants (the “Class D Warrants” and, together with the Class C Warrants, the “Warrants”) to purchase up to 5,000,000 shares of common stock, priced at a public offering price of $1.10 per Common Share, Class C Warrant and Class D Warrant or $999.90 per Preferred Share, 909 Class C Warrants and 909 Class D Warrants.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1372514/000137251423000097/0001372514-23-000097-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Ladenburg Thalmann & Co. Inc."},{"label":"Value","value":"Underwriting Agreement for public offering of common stock, preferred stock, and warrants, net proce"},{"label":"Effective","value":"2023-06-02"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}